Common Reducing Agents in Antibody–Drug Conjugates (ADCs)

Antibody–drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high potency of small-molecule cytotoxins to achieve targeted tumor cell killing, thereby improving efficacy while minimizing systemic toxicity. Compared with unconjugated antibodies or fragments, ADCs can release highly active toxins within the tumor microenvironment and are, in principle, capable of greater therapeutic benefit.

I. Background and Mechanistic Overview

In thiol-based conjugation strategies, a critical step is the controlled reduction of disulfide bonds. Disulfides are key “scaffolds” maintaining antibody higher-order structure; they occur both inter-chain and intra-chain. For example, human IgG1 typically contains ~16 disulfide bonds (about 4 inter-chain and 12 intra-chain). When using thiol coupling, the goal is to selectively open the intended disulfides without disrupting those essential for conformational stability.

II. Common Reducing Agents

In practice, TCEP, β-mercaptoethanol (β-ME), and dithiothreitol (DTT) are widely used. They differ in chemical nature, reaction mechanism, reducing strength/kinetics, stability, and compatibility with subsequent conjugation, and should be chosen to fit the antibody architecture and the process window.

​

Figure 1. Chemical structure of DTT

​

Figure 2. Chemical structure of β-ME

​

Figure 3. Chemical structure of TCEP

III. Chemistry and Mechanisms (Overview)

Reducing agent	Chemical nature	Typical mechanism	Volatility/odor	Usual pH range
TCEP	Trivalent phosphine	Nucleophilic attack by phosphine induces two-electron S–S cleavage (forming phosphine oxide); thiol-free	Very low volatility; no strong odor	1.5–8.5 (near-neutral preferred)
β-ME	Monothiol small molecule	Forms a mixed disulfide via nucleophilic attack, followed by exchange	Strong, irritating odor; volatile	7.0–8.5
DTT	Dithiol	Intramolecular ring formation drives reduction; thermodynamically favorable	Low volatility; mild odor	7.0–8.5 (faster under basic conditions)

IV. Performance Comparison

Reducing agent	Strength	Typical concentration	Typical time
TCEP	Strong (largely irreversible)	5–50 mM	Minutes
β-ME	Weak	10–100 mM	Hours (slow)
DTT	Moderate	1–100 mM	Faster than β-ME, slower than TCEP

V. Safety and Operational Stability

Dimension	TCEP	DTT	β-ME
Toxicity/irritation	Relatively mild	Mucosal/skin irritant	Strong, pungent odor; respiratory irritant
Volatility	Very low	Low	High (a common lab odor source)
Storage & lifetime	Stable in aqueous solution; oxidation-resistant	Oxidizes readily; make fresh	Volatile and oxidizes; aliquot into small vials

VI. Common Issues and Troubleshooting

• DAR too high / aggregates increasing: Reduction time/temperature too aggressive → lower TCEP equivalents or shorten time; add EDTA to suppress metal-catalyzed thiol exchange.
• Low conjugation efficiency: pH too low or under-reduction → adjust to pH 6.8–7.0 and modestly increase TCEP; confirm complete removal of DTT/β-ME residues.
• Re-oxidation → DAR falls back: Excess delay between desalting and conjugation → transfer rapidly to conjugation under inert atmosphere and/or with trace antioxidants.
• Strong odor: β-ME in use → switch to TCEP or DTT; improve ventilation and sealed handling.

Considering stability, controllability, and downstream compatibility, TCEP is increasingly the first-choice mild reducer in ADC processes. DTT fits scenarios requiring rapid, strong reduction when immediate and thorough desalting is feasible. β-ME is mainly used in exploratory lab work or cost-sensitive early trials where odor/safety constraints are less stringent. Looking ahead, more selective, site-specific and milder reduction systems (including enzyme/chemo-assisted disulfide re-engineering) may further improve ADC quality consistency and scalability.

Aladdin: https://www.aladdinsci.com/